Related Experiment Video

Updated: Apr 10, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Antihypertensive Combination Treatment: State of the Art

M Burnier1

  • 1Service of Nephrology and Hypertension, Department of Medicine, University Hospital, Rue du Bugnon 17, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland, michel.burnier@chuv.ch.

Current Hypertension Reports
|June 13, 2015
PubMed

Insights

Single-pill combinations (SPCs) improve hypertension management by reducing pill burden and enhancing efficacy. While offering benefits, their flexibility and cost require consideration in treatment strategies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Adequate blood pressure control is crucial for preventing target organ damage and cardiovascular events in hypertensive patients.
  • A significant number of treated patients remain hypertensive due to factors like medical inertia, poor adherence, and polypharmacy.
  • Current antihypertensive therapies face limitations in achieving optimal blood pressure control in a substantial patient population.

Purpose of the Study:

  • To review the role and place of single-pill combinations (SPCs) in the contemporary management of hypertension.
  • To discuss the advantages and limitations of using SPCs in clinical practice.
  • To assess the impact of recent advancements in SPC development on hypertension treatment.

Main Methods:

  • This review synthesizes current literature on single-pill combinations for hypertension.
  • It analyzes the benefits of SPCs, including reduced pill burden and improved efficacy.
  • The review also considers potential drawbacks such as cost and flexibility.

Main Results:

  • Single-pill combinations (SPCs) containing two or three antihypertensive agents simplify treatment regimens.
  • SPCs can improve patient adherence and treatment efficacy without substantially increasing side effects.
  • The development of new SPCs offers enhanced therapeutic options for physicians.

Conclusions:

  • Single-pill combinations represent a significant advancement in hypertension management.
  • They address key challenges such as medical inertia and poor adherence.
  • SPCs are a valuable tool for improving blood pressure control and reducing cardiovascular risk.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.2K

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
880
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
660
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K